AstraZeneca PLC Rumored to be Eyeing Up US Target, Analysts Believe Cubist Pharmaceuticals, Inc. to be a Possibility

Cubist Pharmaceuticals is a US biopharmaceutical business which sells an antibiotic called Cubicin, used to treat complex skin infections and the “superbug”, MRSA.

It is thought that US sales of Cubicin could eventually top $1bn (£617m) and Cubist’s success in the tough antibiotics market has already marked it out as a possible acquisition target.

Last month, Cubist settled a patent dispute with Israeli drug maker Teva over Cubicin, which lessened the threat of generic competition.

MORE ON THIS TOPIC